Intrathecal Compounding Specialists, LLC, Scott, LA
Is Intrathecal Compounding Specialists, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Intrathecal Compounding Specialists, LLC hold a Louisiana pharmacy license?
State board of pharmacy records for Louisiana are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its credential verification is an interactive search. The Texas State Board of Pharmacy also lists nonresident license 33096 for INTRATHECAL COMPOUNDING SPECIALISTS LLC, SCOTT, LA, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054016786 for INTRATHECAL COMPOUNDING SPECIALISTS, SCOTT, LA, status NOT RENEWED, as of Nov 13, 2026.
Has Intrathecal Compounding Specialists, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Sep 15, 2020), 1 warning letter close-out (Jan 19, 2022), 1 state referral letter (Jan 19, 2022) and 1 FMD-145 letter (Jan 19, 2022) for Intrathecal Compounding Specialists, LLC. State board of pharmacy records for Louisiana are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its credential verification is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Intrathecal Compounding Specialists, LLC
- Location
- Scott, LA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Jan 19, 2022
- FDA Data Dashboard inspections
- 3 inspections: 2 OAI, 1 VAI; 3 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 22 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Intrathecal Compounding Specialists, LLC, a 503A facility, with 6 dated actions.
| Document | |||
|---|---|---|---|
| Jan 19, 2022 | State referral letter | State Referral Letter Issued 01/19/2022 | Not linked by FDA |
| Jan 19, 2022 | FMD-145 letter | FMD-145 Letter Issued 01/19/2022 | Not linked by FDA |
| Jan 19, 2022 | Warning letter close-out | Warning Letter Close Out Issued 01/19/2022 | Not linked by FDA |
| Aug 19, 2021 | Form 483 | 483 Issued 08/19/2021 | FDA copy (archived) |
| Sep 15, 2020 | Warning letter | Warning Letter (09/15/2020) | FDA copy (archived) |
| Feb 14, 2019 | Form 483 | 483 Issued 02/14/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Intrathecal Compounding Specialists, LLC, Scott, LA (FEI number 3006372310), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Aug 19, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3006372310 | 1149221 |
| Feb 14, 2019 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3006372310 | 1081945 |
| Nov 17, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3006372310 | 1034828 |
Form 483s FDA has published for this site
- Aug 19, 2021: Form 483 to Intrathecal Compounding Specialists, LLC, published Jan 18, 2022. fda.gov
- Feb 14, 2019: Form 483 to Intrathecal Compounding Specialists, LLC, published Apr 30, 2019. fda.gov
- Jan 8, 2018: Form 483 to Intrathecal Compounding Specialists, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 22 numbered observations in all, across 3 inspections ending Nov 17, 2017 to Aug 19, 2021. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 9, 2021 to Aug 19, 2021: 3 observations
- Firm on the cover
- Intrathecal Compounding Specialists, LLC, 206a Jacobs Run, Scott, LA 70583-8907
- FEI number
- 3006372310
- Establishment type on the cover
- Producer of Sterile Drug Products
- FDA district office on the cover
- 404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic production.
Specifically,
a) You had four fingertip environmental monitoring results in the ISO 5 environment where you did not identify the microorganism and continued to produce and distribute sterile drug products without a complete investigation and corrective action taken.
Lots Compounded
<Redacted B6> 9/J 6/2020
L
<Redacted B4> 12/9/2020
I
R
Employee
Date
CFUs
L/RHand
L
6/1 4 ,/2021
R
b) Additionally, you lack adequate routine environmental monitoring. You only take surface samples <Redacted B4> and rotate <Redacted B4> fingertip samples between <Redacted B4> employees who compound.
Observation 2
Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.
Specifically,
a) You use <Redacted B4> and <Redacted B4> which are not sterile for daily cleaning of LFHs (ISO 5) and the clean room suite.
b) Additionally, the <Redacted B4> wipes are opened and stored outside the LFHs for multiple days exposing the individual wipes to lesser quality air prior to use inside the LFHs (ISO 5) without any decontamination upon introduction into the LFHs.
Observation 3
Disinfectant contact time (also known as "dwell time") and coverage of the item being disinfected were insufficient to achieve adequate levels of disinfection.
Specifically, during the daily cleaning of the clean room I observed on August 10, 2021, each of your disinfectants <Redacted B4> wipes and spray and <Redacted B4> spray) used within the ISO 5 and ISO 7 environments had a less than <Redacted B4> wet contact time, despite the supplier's established <Redacted B4> minimum contact time needed for the disinfectant to achieve the necessary log reduction of microorganisms.
Inspection dated Feb 14, 2019 by FDA (dates on the form not read): 5 observations
- Firm on the cover
- Intrathecal Compounding Specialists, LLC, 206A Jacob's Run, Scott, LA 70583
- FEI number
- 3006372310
- Establishment type on the cover
- Producer of Sterile Products
- FDA district office on the cover
- 404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard, actions page
- FDA document
- Read the full 483 (PDF on fda.gov); FDA also posts it as https://web.archive.org/web/20250506103522/https://www.fda.gov/media/124419/download
Observation 1
The ISO classified area unde1went a change in air equipment that <Redacted B4> and you continued to produce and distribute sterile diugs.
Specifically, you replaced the <Redacted B4> to the sterile suite on Febrnaiy 6, 2019, due to issues with maintaining the coolness of the air <Redacted B4> on rriultiple occasions). Your fnm continued to produce and distribute sterile drugs while and after the <Redacted B4> to the sterile suite was replaced without adequate cleaning and receitification following the installation.
Observation 2
Inadequate pressure differentials between higher quality air room and lower quality air rooms were observed.
Specifically, you had negative or zero pressure for sho1t periods oftime in the buffer room (ISO 7) and anteroom (ISO 8) on Januaiy 2, 2019. Additionally, there were multiple times on twenty-one days when the pressure was lost in the <Redacted B4> room from November 28, 2018 to December 28, 2018. You have no pressure data for Januai·y 24, 2019 to February 7, 2019 between the anteroom and <Redacted B4> room as well as when the <Redacted B4> was being changed.
Observation 3
The use of sporicidal agents in the cleanrooms and ISO 5 area is inadequate or infrequent.
Specifically, you do not use a sporicidal cleaner at a minimum monthly.
Observation 4
Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worse-case activities and conditions that provide a challenge to aseptic operations.
Specifically, your media fills include <Redacted B4> with minimal manipulations and do not include syringes at all or the number of syringes produced for stock solutions.
Observation 5
Personnel donned gowning apparel improperly, that may have caused the gowning apparel to become contaminated.
Specifically, you don non-sterile face masks in an uncontrolled environment which do not cover your entire face and lean into the ISO 5 hoods during aseptic operations.
Inspection Nov 6, 2017 to Nov 17, 2017: 14 observations
- Firm on the cover
- Intrathec al Compounding Specialist, LL C Jaco bs Run, 206
- FEI number
- 3006372310
- Establishment type on the cover
- Producer of Sterile and Non- sterile Drugs
- FDA district office on the cover
- Not read
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic
production.
Specifically, employees had positive results multiple times for fingertip testing (which is performed every 2 weeks according to SOP), did not identify the microorganism and continued to produce and distribute sterile drug products.
Tech/RPh Date Cf Us <Redacted B6>Y 1/16/2017 l 3/6/2017 1 4/24/2017 I 7/10/2017 I 8/21/2017 1 9/13/2017 I 4/20/2017 I 8/2/2017 I 1/3/2017 2
2/20/2017 3 4/17/2017 1 large
8/30/2017 1 1/3/2017 1 1/18/20 17 3 1/25/2017 1 large 2/8/201 7 ]
4/12/201 7 l 4/19/2017 I 4/26/201 7 . 2 large 5/3/2017 3 5/24/2017 I 7/5/20 17 2 large
9/ 13/2017 I
Observation 2
You produced highly potent drugs without providing adequate segregation, cleaning of work surfaces and cleaning of personnel to prevent cross-contamination.
Specifically, during the inspection I observed the following poor aseptic technique in which personnel did not disinfect and change gloves frequently enough to prevent contamination:
Reaching over items Placing a paper label in the laminar flow hood Touching the plunger of the syringe Multiple products with multiple active ingredients and multiple active pharmaceutical ingredients (bulk solutions) are in the laminar flow hood at the same time with no segregation/separation to prevent mix-ups
Observation 3
Personnel touched equipment or other surfaces located outside of the .ISO 5 classified aseptic processing area with gloved hands and then engaged in aseptic processing without changing or sanitizing gloves .
Observation 4
Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.
Specifically, during the inspection I observed an employee touch the outside of their gloves with their bare hand, did not disinfect and continued to compound sterile drugs which were further distributed.
Observation 5
Personnel engaged in aseptic processing were observed with exposed hair and exposed mouth.
Specifically, portions of your face and neck were exposed to the ISO 5 environment during aseptic operations.
Observation 6
Personnel engaged in aseptic processing were observed leaving and re-entering the cleanroom from non- classified areas without first replacing gowning apparel.
Specifically, you reuse the same fluid resistant gown throughout the day.
Observation 7
Equipment was and Materials or supplies were not disinfected prior to entering the aseptic processing areas.
Specifically, supplies, materials and equipment are not decontaminated prior to entering the ISO 5 and ISO 7 environments.
Observation 8
Non-microbial contamination was observed in your production area.
Specifically, the HEPA filter in the laminar flow hood was observed to be stained brown in areas directly behind the compounding area.
Observation 9
The ISO 5 classified aseptic processing areas had difficult to clean and particle-generating equipment or surface.
Specifically, I observed threads stuck in the outlet cover in the laminar flow hood which was used throughout this inspection to compound and distribute sterile drugs.
Observation 10
Disinfectant contact time (also known as "dwell time") and coverage of the item being disinfected were insufficient to achieve adequate levels of disinfection.
Specifically,
Contact times for each cleaning agent were not followed as observed during this inspection . Employees were observed to clean front to back and used the same wipe multiple time . Employees were observed to clean during operations using the same portion of one wipe between products one section of the surface of the laminar flow hood.
Observation 11
lS0-5 classified areas were not certified under dynamic conditions.
Specifically, unidirectional airflow was not verified under operational conditions. Your certification of ISO 5 and ISO 7 areas do not include smoke studies, airflow patterns, HEPA leaking testing and air exchange for the anteroom.
Observation 12
You have no assurance that the endotoxin level of your intrathecal drug products are safe, since you do not have any cndotoxin data and your finn doesn't perform endotoxin testing for the finished product. These preparations are made using non-sterile starting material. Furthermore, there is no endotoxin testing data for your hulk solutions (active pharmaceutical ingredients) past the initial compounded date.
Observation 13
Post filtration integrity testing to the sterilizing filter was not performed.
Observation 14
Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.
State board of pharmacy records
State board of pharmacy records for Louisiana are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its credential verification is an interactive search.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).
| License | Type as the board gives it | Name on the board record | Location | Status | Prior disciplinary orders (file flag) |
|---|---|---|---|---|---|
| 33096 | Non Resident Sterile Compounding | INTRATHECAL COMPOUNDING SPECIALISTS LLC | SCOTT, LA | Active | No |
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054016786 | LICENSED PHARMACY | INTRATHECAL COMPOUNDING SPECIALISTS | SCOTT, LA | NOT RENEWED |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Texas State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Texas State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.